Novavax and Johnson & Johnson Seek Regulatory Approval for COVID-19 Vaccines After Posting Promising Efficacy Data

Vaccine candidates from Novavax and Johnson & Johnson are looking to join the growing list of authorized COVID-19 vaccines as the companies recently posted positive efficacy data from large-scale Phase III trials evaluating their respective vaccines. Shots from both companies could also offer protection against some of the new circulating variants of SARS-CoV-2, which is welcome news in light of their increasing spread around the world.